We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Olema Pharmaceuticals Inc | NASDAQ:OLMA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.70 | -6.45% | 10.15 | 10.10 | 10.34 | 11.40 | 9.7001 | 11.40 | 1,170,868 | 23:55:25 |
Details of the SABCS 2023 poster presentations are:
Title: | A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer. |
Poster ID: | PO4-04-12 |
Session Title: | Poster Session 4 |
Date & Time: | Thursday, December 7, 2023, 5:00 – 7:00 p.m. CT |
Location: | Halls 2-3 |
Title: | A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients. |
Presenter: | Arlene Chan, FRACP, MMed, Breast Cancer Research Centre-WA, Curtin University, Breast Clinical Trials Unit, Hollywood Private Hospital, Nedlands, Australia |
Poster ID: | PS15-04 |
Session Title: | Novel Nuclear Receptor Targeting Therapies |
Date & Time: | Thursday, December 7, 2023, 5:30 – 6:30 p.m. CT |
Location: | Stars at Night Ballroom 1-2 |
Title: | OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of-care treatment for ER+, HER2- advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy. |
Poster ID: | PO3-18-09 |
Session Title: | Poster Session 3 |
Date & Time: | Thursday, December 7, 2023, 12:00 – 2:00 p.m. CT |
Location: | Halls 2-3 |
A copy of the presentations will be made available on Olema’s website under the Science section when it is presented at the symposium. Abstracts for the posters can be found on the SABCS 2023 website here.
Company Investor Webcast and Conference Call
Olema will host a webcast and conference call for analysts and investors to review data presented at SABCS 2023 as well as other ongoing studies on Friday, December 8, 2023, at 8:00 a.m. ET (7:00 a.m. CT). Please register for the webcast by visiting the Investors & Media section of Olema’s website at olema.com.
About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 3 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com, or follow us on Twitter and LinkedIn.
Contact:Geoffrey Mogilner, Vice President, Investor Relations and Communicationsir@olema.com
1 Year Olema Pharmaceuticals Chart |
1 Month Olema Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions